British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy

HIV Medicine

Volumn 2, Issue 4, 2001, Pages 276-313

  Pozniak, A ^a   Gazzard, B ^a   Babiker, A ^a   Churchill, D ^a   Collins, S ^a   Deutsch, J ^a   Fisher, M ^a   Johnson, M ^a   Khoo, S ^a   Loveday, C ^a   Main, J ^a   Matthews, G ^a   Moyle, G ^a   Nelson, M ^a   Peters, B ^a   Phillips, A ^a   Pillay, D ^a   Poppa, A ^a   Taylor, C ^a   Williams, I ^a   Youle, M ^a   more..

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYCLOSPORIN A; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MYCOPHENOLIC ACID; NELFINAVIR; NEVIRAPINE; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STEROID; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CRYSTALLURIA; DIARRHEA; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG POTENCY; DRUG TOLERABILITY; DRY SKIN; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOPHILIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL NEPHRITIS; LIPODYSTROPHY; LYMPHOCYTE COUNT; METHODOLOGY; NAIL DISEASE; NAIL DYSTROPHY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; SALVAGE THERAPY; SYMPTOMATOLOGY; TERATOGENICITY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; EVIDENCE-BASED MEDICINE; GLUCOSE INTOLERANCE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; PATIENT SELECTION; RESEARCH DESIGN; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035202568     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-2662.2001.00083.x     Document Type: Article

References (183)

1. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy
2. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel
3. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
4. Randomized trials or observational tribulations?
5. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
6. Legal and political considerations of clinical practice guidelines
7. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
8. Surrogacy in HIV-1 clinical trials
9. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
10. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta trial: An extended virology study
11. AIDS across Europe, 1994-98: The EuroSIDA study
12. Changing patterns of mortality across Europe in patients infected with HIV-1
13. Risk of new AIDS diseases in people on triple therapy
14. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after the initiation of highly active antiretroviral therapy in HIV infection
15. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
16. Association of viral load, CD4 cell count, and treatment with clinical progression in HIV patients with very low CD4 counts: The EuroSIDA study
17. Surrogate end points in clinical trials: Are we being misled?
18. Perspective: Validating surrogate markers: Are we being naive?
19. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome
20. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
21. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
22. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
23. Trial design in the era of highly active antiretroviral combinations for HIV infection
24. 10 reduction in clinical trials
25. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
26. A controlled trial of zidovudine in primary human immunodeficiency virus infection
27. Genotypic and phenotypic characterization of HIV-1 patients with primary infection
28. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
29. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type-1 infection on viral replication and antiviral immune responses
30. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
31. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
32. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
33. Immune control of HIV-1 after early treatment of acute infection
34. Immune control of HIV-1 replication
35. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
36. Control of HIV despite the discontinuation of antiretroviral therapy
37. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug
38. Effect of cyclosporin A in combination with highly active antiretroviral therapy in primary HIV-1 infection
39. Structured treatment interruption: State-of-the-art lecture
40. Prolonged HAART initiated within 120 days of infection does not result in sustained control of HIV-1 after cessation of therapy
41. The occurrence of lipodystrophic phenomena in patients with primary HIV infection (HIV) treated with antiretroviral therapy (ARV)
42. Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection
43. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection
44. Analysis of prevalence of HIV, -1 drug resistance in primary infections with the UK
45. Will we ever know when to treat HIV infection?
46. CD4 cell counts in adults with newly diagnosed HIV infection results of surveillance in England and Wales, 1990-98
47. 3
48. CD4+ lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART
49. Late initiation of antiretroviral therapy (at CD4+ lymphocyte count <200 cells/μL) is associated with increased risk of death
50. Viral load changes in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load
51. When to start HAART in chronically HIV-infected patients? A collection of pieces of evidence from the I.C.O.N.A. study
52. Sustained efficacy of nevirapine (NVP) in combination with two nucleosides in advanced treatment-naive HIV infected patients with high viral loads: A B1090 substudy
53. 3
54. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: Post hoc results from Study 006
55. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection
56. Comparison of antiviral response with abacavir/Combivir to indinavir/Combivir in therapy-naive adults at 48 weeks (CNA3005)
57. The SPICE study. 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues
58. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
59. ABT-378/ritonavir (ABT-378/r) versus nelfinavir in antiretroviral naive subjects: Week 48 comparison in a phase III blinded randomized clinical trial
60. Treatment failure changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
61. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
62. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
63. Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine
64. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
65. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
66. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
67. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine
68. Safety of Kaletrat: Results from phase II and III clinical trials
69. A randomised controlled clinical trial to evaluate whether therapeutic drug monitoring (TDM) contributes to reduced HIV related mortality
70. A randomized study comparing continued indinavir (800 mg tid) vs switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside Safety Trial (BEST)
71. Comparative pharmacokinetics of twice daily (BID) Fortovase/ritonavir and Invirase/ritonavir
72. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
73. Management of protease inhibitor (PI)-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons
74. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients
75. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
76. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash
77. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids
78. The effects of a short course of prednisone on the incidence of rash associated with nevirapine (Viramune)
79. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
80. CD4-cell counts in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
81. Abacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir in HIV-1-infected antiretroviral therapy-naive adults. Preliminary results of a 48-week open label study (CNA3014)
82. Impact of directly observed therapy on long-term outcomes in HIV clinical trials
83. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
84. Adherence to HAART predicts progression to AIDS
85. Adverse effects of antiretroviral therapy
86. Quality of life outcomes of combination zidovudine/didanosine/nevirapine and zidovudine/didanosine for antiretroviral-naive advanced HIV-infected patients
87. Adherence: A necessity for successful HIV combination therapy
88. Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease
89. Potential advantages of a compact triple nucleoside regimen: Efficacy and adherence with Combivir/abacavir versus Combivir/indinavir in an open-label randomised comparative study (CNAB3014)
90. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
91. Do patients' beliefs about HAART influence adherence?
92. Patient characteristics and attitudes associated with antiretroviral (AR) adherence
93. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications
94. Adherence to HIV combination therapy
95. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
96. Diabetes. Exploding type II
97. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
98. Lactic acidosis complicating the acquired immunodeficiency syndrome
99. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy
100. Hyperlactatemia and hepatic abnormalities in 10 immunodeficiency virus infected patients receiving nucleoside analogue combination regimens
101. Survival of a human immunodeficiency virus patient with nucleoside-induced lactic acidosis: Role of haemodialysis treatment
102. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis
103. Riboflavin and severe lactic acidosis
104. Therapeutic drug monitoring (TDM) of indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: Results from ATHENA
105. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virological relapse on antiretroviral therapy
106. Lower level HIV viral rebound and blips in patients receiving potent antiretroviral therapy
107. Prevalence and predictive value of intermittent viraemia in patients with viral suppression
108. Delayed immunologic deterioration among patients who virologically fail protease inhibitor-based therapy
109. Comparison of time to achieve HIV RNA < 400 copies/mL and <50 copies/mL in a phase III blinded randomised clinical trial of Kaletra versus nelfinavir in ARV naive patients
110. Intensification of stable background therapy with abacavir, preliminary 48 week data
111. ABT378/ritonavir (ABT378/r) suppresses HIV RNA to <400 copies per ml in 84% of PI experienced patients at 4 weeks
112. Durable anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP266) in combination with indinavir (IDV) (DMP266-003 cohort IV)
113. Incidence and predictors of clinical progression among HIV-infected patients experiencing virologic failure of protease inhibitor-based regimens
114. Baseline and week 48 final phenotypic analysis of HIV-1 from patients adding tenofovir disoproxil fumarate (TDF) therapy to background ART
115. Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor based HAART
116. Drug-resistance genotyping in HIV-1 therapy: The Viradapt randomised controlled trial
117. A randomised study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study team for the Terry Beirn Community Programs for Clinical Research on AIDS
118. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomised trial (VIRA3001)
119. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomised trial (NARVAL, ANRS 088)
120. A prospective, randomised study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): Final 6 month results
121. Impact of drug resistance on virologic response to salvage therapy. Swiss HIV Cohort Study
122. Phenotypic analysis of the Viradapt study: Correlation with genotypic resistance and PI plasma levels
123. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient
124. ABT378/ritonavir and efavirenz. 24 weeks' safety/efficacy evaluation in nelfinavir PI-experienced patients
125. Surrogate marker responses to multidrug combination hydroxyurea, efavirenz, double protease inhibitors and analogues in protease inhibitor failures
126. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
127. Virologic responses to a ritonavir/saquinavir-containing regimen in patients who had previously failed nelfinavir
128. ABT-378/ritonavir (ABT-378/r) and efavirenz: One year safety/efficacy evaluation in multiple PI-experienced patients
129. Evaluation of ABT-378/ritonavir (ABT-378/r) based salvage regimens in a cohort of HIV-infected patients
130. Analysis of HIV phenotypic cross resistance to protease inhibitors in patients failing on combination therapies
131. Salvage therapy using six drugs in heavily pretreated patients
132. Antiretroviral intensification accelerates the decay of the latent reservoir of HIV-1 and decreases but does not eliminate ongoing virus replication
133. Assessment of HIV-1-specific T cell responses in primary and acute infection and effects of HAART in early treatment
134. A prospective trial of strategic treatment interruptions in 128 patients
135. Short-cycle intermittent HAART. A pilot study
136. Host factors in the pathogenesis of HIV disease: Implications for therapeutic strategies
137. Response to salvage therapy in patients undergoing a structured treatment interruption
138. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study
139. Association between the level of plasma HIV RNA and long-term increase of CD4+ cell counts in a cohort of HIV-infected patients initiating a protease inhibitor-containing regimen
140. Protease inhibitor resistant HIV-1 has marked decreased fitness in vivo
141. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up
142. Control of SIV rebound through structured treatment interruptions during early infection
143. Utility of HIV genotyping and clinical expert advice: The Havana trial
144. Use of genotypic resistance to guide HIV therapy: Clinical impact and cost-effectiveness
145. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
146. Resistance associated mutations in subtype C HIV-1 protease gene from treated and untreated patients in the United Kingdom
147. Patterns of drug resistance: Do we need to adjust treatment to clade?
148. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting
149. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
150. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
151. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients
152. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) 1250mg BID in treatment-naive patients improves therapeutic outcome after 1 year: Results from ATHENA
153. Urological complaints in relation to indinavir plasma concentration in HIV-infected patients
154. Protease inhibitors and unusual bleeding in haemophiliacs
155. Increased bleeding associated with PI therapy in HIV-positive patients with bleeding disorders
156. Evidence of sexual transmission of hepatitis C virus (HCV) in a cohort of homosexual men
157. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus
158. False-negative hepatitis C antibody is associated with low CD4 cell counts in HIV/HCV co-infected patients
159. Liver fibrosis progression in human immunodeficiency virus and hepatitis C co-infected patients
160. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
161. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
162. Mortality from liver cancer and liver disease in haemophiliac men and boys in the UK given blood products contaminated with hepatitis C
163. High hepatitis C viraemia and impaired antibody response in patients co-infected with HIV
164. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
165. Efficacy and safety of combination therapy with interferon-A2b and ribavirin from chronic hepatitis C in HIV-infected patients
166. Combination treatment with interferon and ribavirin for hepatitis C in HIV co-infection patients
167. Efficacy of interferon plus ribavirin combination treatment and impact on HIV infection in hemophiliacs with chronic hepatitis C and under HAART
168. Ribavirin antagonizes the effect of azidothymidine on HIV replication
169. Peginterferon alfa-2 in patients with chronic hepatitis C
170. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
171. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials
172. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4+ levels, hepatitis B and C positivity, and baseline liver function tests
173. British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy 1998
174. Influence of age on CD4 cell recovery in HIV-infected patients receiving HAART
175. Severe liver toxicity in patients receiving two nucleoside analogues and a nonnucleoside reverse transcriptase inhibitor